Biogen (BIIB) EBIT Growth (3y) (2012 - 2026)
Powered by 
Analysis
Biogen (BIIB) EBIT Growth (3y) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | 9.40% |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | -102.00% |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | 6.70% |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | 8.36% |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | 89.72% |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | 24.14% |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | 44.34% |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | -96.48% |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | - |
| 10 | Insmed | 28.06 Bn | 26.90 Bn | 358.27 Mn | 81.27% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -96.48% |
| Mar 31, 2026 | -8.06% |
| Dec 31, 2025 | -48.19% |
| Sep 30, 2025 | -28.66% |
| Jun 30, 2025 | -43.86% |
| Mar 31, 2025 | -36.10% |
| Dec 31, 2024 | -35.67% |
| Sep 30, 2024 | -30.77% |
| Jun 30, 2024 | -32.00% |
| Mar 31, 2024 | -27.64% |
| Dec 31, 2023 | 33.63% |
| Sep 30, 2023 | -39.88% |
| Jun 30, 2023 | -61.19% |
| Mar 31, 2023 | -28.53% |
| Dec 31, 2022 | -37.22% |
| Sep 30, 2022 | -20.68% |
| Jun 30, 2022 | -26.22% |
| Mar 31, 2022 | -25.93% |
| Dec 31, 2021 | -25.90% |
| Sep 30, 2021 | -22.38% |